An Evaluation of Efficacy and Safety of Tofacitinib, A JAK Inhibitor in the Management of Hospitalized Patients with Mild to Moderate COVID-19 - An Open-Label Randomized Controlled Study.

Murugesan, Hema; Cs, Gauthaman; Nasreen, H Sadiqa; Santhanam, Sham; M, Gowrishankar; Ravi, Sailatha; Es, Sharanya Shre

Murugesan, Hema; Cs, Gauthaman; Nasreen, H Sadiqa; Santhanam, Sham; M, Gowrishankar; Ravi, Sailatha; Es, Sharanya Shre.

Afiliación

Murugesan H; Assistant Professor of Rheumatology, Stanley Medical College, Chennai, Tamil Nadu.
Cs G; Associate Professor, Department of General Medicine, Pulmonology, Dr. VRE Research Laboratories, Chennai, Tamil Nadu.
Nasreen HS; Postgraduate, General Medicine, Stanley Medical College, Chennai, Tamil Nadu.
Santhanam S; Consultant rheumatologist, Global Glenegal Hospital, Chennai, Tamil Nadu.
M G; Postgraduate, SPM Department, Stanley Medical College, Chennai, Tamil Nadu.
Ravi S; Director, Pharmacogenomics, Dr. VRE Research Laboratories, Chennai, Tamil Nadu.
Es SS; Researcher, Pulmonology, Dr. VRE Research Laboratories, Chennai, Tamil Nadu.

J Assoc Physicians India ; 69(12): 11-12, 2022 Dec.

Article en En | MEDLINE | ID: mdl-35057599

Asunto(s)

COVID-19; Inhibidores de las Cinasas Janus; Adulto; Humanos; Agentes Inmunomoduladores; Piperidinas; Inhibidores de Proteínas Quinasas/efectos adversos; Pirimidinas; Pirroles/efectos adversos; ARN Viral; SARS-CoV-2; Resultado del Tratamiento

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de las Cinasas Janus / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Assoc Physicians India Año: 2022 Tipo del documento: Article

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links